Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?

(2019) Michael P. Kim et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis

(2019) Quisette P Janssen et al.   JNCI-Journal of the National Cancer Institute

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

(2019) Janet E. Murphy et al.   JAMA Oncology

Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement

(2019) Ijin Joo et al.   RADIOLOGY

PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

(2018) Paula Ghaneh et al.   HEALTH TECHNOLOGY ASSESSMENT

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

(2018) Janet E. Murphy et al.   JAMA Oncology

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen

(2017) Changhoon Yoo et al.   Oncotarget

Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer

(2016) Marek Sierzega et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer

(2015) Fausto Petrelli et al.   PANCREAS

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

(2013) Helmut Oettle et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin

(2009) Fiona Campbell et al.   HISTOPATHOLOGY